Based in Sunnyvale, CA, Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

Type
Public
HQ
Sunnyvale, US
Founded
1996
Employees
1,700 (est)
Cepheid was founded in 1996 and is headquartered in Sunnyvale, US

Cepheid Locations

Sunnyvale, US

Cepheid Metrics

Cepheid Summary

Market capitalization

$3.87 B

Closing share price

$53
Cepheid's current market capitalization is $3.87 B.

Cepheid Financials

Cepheid's revenue is $539 M in FY, 2015 which is 14.56% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$401 M$470 M$539 M

Gross profit

$193 M$241 M$269 M

Operating income

$-16 M$-34.1 M$-30.9 M

Operating expense total

$209 M$275 M$300 M

Net Income

$-18 M$-50.1 M$-48.5 M

Operating cash flow

$-29.7 M$30.6 M$15.9 M

    Cepheid Market Value History

    Cepheid Online Presence

    Cepheid News

    Cepheid Company Life

    You may also be interested in